Services
Patti is an accomplished life sciences and pharmaceutical lawyer who has helped numerous clients grow and bring their innovations to market over her almost 30-year career at Wiggin and Dana. She is Chair of the Life Sciences Practice and a Partner in the firmโs Corporate Department and the Mergers and Acquisitions Practice. Patti is also a member of the firmโs Pro Bono Committee and a past member of the firmโs Executive Committee. She is also a member of wiggin(x).
Pattiโs work has earned multiple honors and recognition, including consistently being named a โLife Science Starโ for mergers and acquisitions and for licensing and collaborations in LMG Life Sciences, Finance Monthlyโs Deal Maker of the Year, and the Pro Bono Partnershipโs Volunteer of the Year. She is also a James W. Cooper Fellow of the Connecticut Bar Foundation and former Vice-Chair of Women in Bioโs Metro New York Chapter.
Her extensive experience spans large multinational pharmaceutical, biotechnology, and medical device companies to world-class universities, emerging biotechnology companies, scientists, and entrepreneurs. She counsels clients in cross-border mergers and acquisitions, global licenses and strategic alliances, research and development arrangements, including clinical trial programs, manufacturing agreements and other commercial contracts.
Before joining Wiggin and Dana, Patti practiced law in the New York office of the Swedish law firm Mannheimer Swartling.
She received her J.D. from the University of Chicago Law School and graduated summa cum laude and Phi Beta Kappa from Lehigh University.
Education
- University of Chicago Law School (J.D., 1987)
- Lehigh University (B.A., 1984)
- Phi Beta Kappa
- summa cum laude
Bar Admissions
Distinctions
Awards and Recognitions
Services
News
Services
Publications
Services
Events
Services
Podcasts
Sorry, No posts.
Experience
- Represented Pathos AI, Inc. in its exclusive, worldwide license to Prelude Therapeuticsโ PRT811 program. PRT811 is a protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor.ย The compound is initially focused on treating patients with recurrent high-grade glioma and uveal melanoma. Pathos is an AI-enabled drug discovery and development company focused on rapidly bringing personalized medicines to patients.
- Represented Affibody AB in its Collaboration and License Agreement with Chiesi Farmaceutici S.p.a. to develop novel Affibodyยฎ molecules as innovative treatments for respiratory diseases. Affibody is eligible to receive upfront, development, regulatory and commercial milestones of up to $214 million plus royalties on sales of the first program and up to $637 million plus royalties if the program is expanded to encompass two additional programs.
- Represented Pathos AI, Inc. (Pathos) in its license from Forma Therapeutics, Inc., a subsidiary of Novo Nordisk, of all rights, title and interest in Formaโs CBP/p300 inhibitor for the treatment of metastatic castration-resistant prostate cancer and other diseases.
- Represented Rallybio Corporation in its Research and Development Collaboration Agreement with AbCellera Biologics Inc. to discover, develop and commercialize antibody-based therapeutics for rare diseases using AbCelleraโs antibody discovery platform to identify product candidates. Under the terms of the agreement, AbCellera and Rallybio will co-develop up to five rare disease therapeutic targets, which will be chosen together by both companies. The collaboration will allow Rallybio to add product candidates to its existing pipeline and also provides the option for AbCellera to conduct process development and clinical manufacturing activities. The partnershipโs first program will focus on addressing the significant unmet therapeutic needs of patients with rare metabolic diseases.
- Represented BioInvent International AB in its exclusive option and license agreement with Exelixis, Inc. to develop novel antibody-based immuno-oncology therapies. The collaboration is intended to expand Exelixisโ portfolio of antibody-based therapies and will combine BioInventโs antibody and cancer immunology expertise with Exelixisโ expertise and resources in antibody engineering and antibody-drug conjugate (ADC) technologies. BioInvent will be responsible for target and antibody discovery and characterization activities using BioInventโs proprietary n-CoDeRยฎ antibody library and F.I.R.S.Tโข screening platform, which rapidly screens samples from patients with cancer to identify antibodies and targets with promising therapeutic potential. Exelixis will pay BioInvent an upfront fee of $25 million in exchange for rights to select three targets. Once Exelixis exercises its option, it will pay BioInvent an option exercise fee and will assume responsibility for all future development and commercialization activities for the associated candidates, including potential ADC and bispecific antibody engineering activities. Additionally, BioInvent will be eligible for success-based development and commercialization milestones, as well as tiered royalties on the net sales of any products that are successfully commercialized.
- Represented Rallybio Corporation in its acquisition of worldwide exclusive rights to Sanofiโs KY1066 (RLYB331 going forward), a preclinical potentially first-in-class antibody. RLYB331 has the potential to address a significant unmet need for patients with severe anemia with ineffective erythropoiesis and iron overload, such as beta thalassemia (BT) and a subset of myelodysplastic syndromes (MDS), amongst others.
- Represented Affibody AB in its license and collaboration agreements withย ACELYRIN, Inc.ย andย Inmagene Biopharmaceuticalsย to develop and commercialize Affibodyโs product, izokibep or ABY-035, a bispecific molecule targeting Interleukin-17A (IL-17), for multiple auto-immune diseases. Under the terms of the ACELYRIN agreement, Affibody received a $25 million upfront payment and is eligible to receive up to $280 million in additional regulatory and sales milestones, plus royalties on sales in the markets covered by the agreement. Under the terms of the Inmagene agreement, Affibody received a $10 million upfront payment and is eligible to receive up to $215.5 million in additional regulatory and sales milestones, plus royalties on sales in several major Asian markets.
- Representedย Notable Labs, Inc.ย in the acquisition of development and commercialization rights in Volasertib fromย Oncoheroes Biosciences Inc. for uses that include leukemias and lymphomas, including acute myeloid leukemia (AML). Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in AML and other tumor types with significant unmet medical needs. Notable intends to leverage its proprietary predictive precision medicines platform to accelerate clinical trial timelines and maximize patient outcomes.
- Representedย Photocure ASAย in its agreement withย Ipsen Pharma SAS for the return of Hexvixยฎ sales, marketing and distribution rights in Europe and other markets that had been controlled by Ipsen. Hexvix is Photocureโs optical molecular imaging agent for the diagnosis of bladder cancer. Starting in 2011, Ipsen served as a strategic partner and has built a solid position for the brand in select key European markets. Photocure regained the global commercialization of Hexvix.
- Representedย Photocure ASAย in its agreements with Asieris Meditech Co., Ltdย for exclusive rights to register and commercialize Hexvix in Mainland China and Taiwan, and worldwide license rights to develop and commercialize Photocureโs product, Ceviraยฎ. Cevira is a fully integrated drug delivery and light device, for the treatment of HPV-induced cervical precancerous lesions and has the potential to be developed into the standard of care for the treatment of HPV infections and precancerous lesions.
- Representedย Swedish Orphan Biovitrum AB (publ) (Sobi) in its expanded agreement with Sanofi to exercise early opt-in for the development and commercialization of BIVV001, an investigational extended half-life factor VIII therapy with the potential to provide once-weekly dosing for people with hemophilia A. Sobi will make a payment to Sanofi of $50 million and will become a development partner in the program. Upon approval in the EU, Sobi will pay the balance of the development costs incurred for BIVV001. Under the agreement, Sobi will pay Sanofi royalties on direct sales in the Sobi territory (Europe, North Africa, certain countries in the Middle East, and Russia) and receive royalties from Sanofi on direct sales in North America and other markets in the Sanofi territory.
- Representedย AptarGroup, Inc. in its acquisition of substantially all of the operating assets and proprietary portfolio ofย Cohero Health, Inc.,ย a digital respiratory health company.
- Represented Rallybio, LLC in its (i) collaboration with artificial intelligence (AI) drug discovery companyย Exscientia to form a joint venture โ called RE Ventures โ that will use AI to accelerate discovery of small molecule drug candidates for undisclosed rare disease indications, and (ii) acquisition of two orphan drug programs, NAITgam and a follow-on therapy, fromย Prophylix AS, for the treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially disabling or life-threatening disorder in fetuses and newborns.
- Representedย Olink Proteomics Holding AB in the sale ofย Olink Proteomicsย toย Summa Equity, a Swedish-based private equity firm that focuses on investments in companies that help solve global challenges.ย Olink Proteomics is a life science company that has developed a unique technology for human biomarker discovery.ย Olinkโs purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide.
- Representedย Swedish Orphan Biovitrum ABย in its exclusive license and acquisition of global rights for emapalumab fromย Novimmune SA. Emapalumab is a late stage orphan drug candidate that addresses a high unmet medical need in primary haemophagocytic lymphohistiocytosis, a rare and life-threatening syndrome of extreme immune activation. Under the terms of the agreement, SOBI made an upfront payment of 50 million Swiss francs and will make additional milestone payments of 400 million Swiss francs.
- Representedย BioInvent International ABย in its collaboration and license agreement withย Pfizer Inc. to undertake a research collaboration to discover and develop novel immuno-regulatory antibodies to treat cancer. BioInvent will apply its unbiased translational drug discovery platform (โF.I.R.S.T.โ) to identify novel oncology targets and therapeutic antibodies targeting tumor-associated myeloid cells. BioInvent received approximately $10 million in early payments, including an upfront payment, early research funding and an equity investment. Assuming five antibodies are developed through to commercialization, BioInvent would be eligible for potential future development milestone payments of more than $0.5 billion through the term of the deal, as well as double digit royalties on sales of products that result from the collaboration.